Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter
  • Published:

STAT3 inhibition of gluconeogenesis is downregulated by SirT1

Abstract

The fasting-activated longevity protein sirtuin 1 (SirT1, ref. 1) promotes gluconeogenesis in part, by increasing transcription of the key gluconeogenic genes pepck1 and g6pase2,3, through deacetylating PGC-1α and FOXO1 (ref. 4). In contrast, signal transducer and activator of transcription 3 (STAT3) inhibits glucose production by suppressing expression of these genes5,6. It is not known whether the inhibition of gluconeogenesis by STAT3 is controlled by metabolic regulation. Here we show that STAT3 phosphorylation and function in the liver were tightly regulated by the nutritional status of an animal, through SirT1-mediated deacetylation of key STAT3 lysine sites. The importance of the SirT1–STAT3 pathway in the regulation of gluconeogenesis was verified in STAT3-deficient mice in which the dynamic regulation of gluconeogenic genes by nutritional status was disrupted. Our results reveal a new nutrient sensing pathway through which SirT1 suppresses the inhibitory effect of STAT3, while activating the stimulatory effect of PGC-1α and FOXO1 on gluconeogenesis, thus ensuring maximal activation of gluconeogenic gene transcription. The connection between acetylation and phosphorylation of STAT3 implies that STAT3 may have an important role in other cellular processes that involve SirT1.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Figure 1: SirT1 is involved in regulating STAT3 acetylation.
Figure 2: STAT3 phosphorylation and transactivation were downregulated by SirT1.
Figure 3: Critical novel acetylation sites regulate STAT3 phosphorylation and transactivation.
Figure 4: Liver-STAT3 deficiency disrupted fasting/SirT1 controlled gluconeogenesis.
Figure 5: The 4K/R mutant STAT3 is defective in suppressing hepatic gluconeogenesis.

Similar content being viewed by others

References

  1. Luo, J. et al. Negative control of p53 by Sir2α promotes cell survival under stress. Cell 107, 137–148 (2001).

    Article  CAS  Google Scholar 

  2. Rodgers, J. T. et al. Nutrient control of glucose homeostasis through a complex of PGC-1α and SIRT1. Nature 434, 113–118 (2005).

    Article  CAS  Google Scholar 

  3. Banks, A. S. et al. SirT1 gain of function increases energy efficiency and prevents diabetes in mice. Cell Metab. 8, 333–341 (2008).

    Article  CAS  Google Scholar 

  4. Frescas, D., Valenti, L. & Accili, D. Nuclear trapping of the forkhead transcription factor FoxO1 via Sirt-dependent deacetylation promotes expression of glucogenetic genes. J. Biol. Chem. 280, 20589–20595 (2005).

    Article  CAS  Google Scholar 

  5. Inoue, H. et al. Role of STAT-3 in regulation of hepatic gluconeogenic genes and carbohydrate metabolism in vivo. Nature Med. 10, 168–174 (2004).

    Article  CAS  Google Scholar 

  6. Inoue, H. et al. Role of hepatic STAT3 in brain-insulin action on hepatic glucose production. Cell Metab. 3, 267–275 (2006).

    Article  CAS  Google Scholar 

  7. Zhong, Z., Wen, Z. & Darnell, J. E. Jr Stat3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6. Science 264, 95–98 (1994).

    Article  CAS  Google Scholar 

  8. Ray, S., Boldogh, I. & Brasier, A. R. STAT3 NH2-terminal acetylation is activated by the hepatic acute-phase response and required for IL-6 induction of angiotensinogen. Gastroenterology 129, 1616–1632 (2005).

    Article  CAS  Google Scholar 

  9. Wang, R., Cherukuri, P. & Luo, J. Activation of Stat3 sequence-specific DNA binding and transcription by p300/CREB-binding protein-mediated acetylation. J. Biol. Chem. 280, 11528–11534 (2005).

    Article  CAS  Google Scholar 

  10. Yuan, Z. L., Guan, Y. J., Chatterjee, D. & Chin, Y. E. Stat3 dimerization regulated by reversible acetylation of a single lysine residue. Science 307, 269–273 (2005).

    Article  CAS  Google Scholar 

  11. Rodgers, J. T., Lerin, C., Gerhart-Hines, Z. & Puigserver, P. Metabolic adaptations through the PGC-1α and SIRT1 pathways. FEBS Lett. 582, 46–53 (2008).

    Article  CAS  Google Scholar 

  12. Chen, D. et al. Tissue-specific regulation of SIRT1 by calorie restriction. Genes Dev. 22, 1753–1757 (2008).

    Article  CAS  Google Scholar 

  13. Solomon, J. M. et al. Inhibition of SIRT1 catalytic activity increases p53 acetylation but does not alter cell survival following DNA damage. Mol. Cell. Biol. 26, 28–38 (2006).

    Article  CAS  Google Scholar 

  14. Chan, J. H., Lim, S. & Wong, W. S. Antisense oligonucleotides: from design to therapeutic application. Clin. Exp. Pharmacol. Physiol. 33, 533–540 (2006).

    Article  CAS  Google Scholar 

  15. Savage, D. B. et al. Reversal of diet-induced hepatic steatosis and hepatic insulin resistance by antisense oligonucleotide inhibitors of acetyl-CoA carboxylases 1 and 2. J. Clin. Invest. 116, 817–824 (2006).

    Article  CAS  Google Scholar 

  16. Puigserver, P. et al. Insulin-regulated hepatic gluconeogenesis through FOXO1-PGC-1α interaction. Nature 423, 550–555 (2003).

    Article  CAS  Google Scholar 

  17. Nakae, J., Park, B. C. & Accili, D. Insulin stimulates phosphorylation of the forkhead transcription factor FKHR on serine 253 through a Wortmannin-sensitive pathway. J. Biol. Chem. 274, 15982–15985 (1999).

    Article  CAS  Google Scholar 

  18. Howitz, K. T. et al. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature 425, 191–196 (2003).

    Article  CAS  Google Scholar 

  19. Li, X. et al. SIRT1 deacetylates and positively regulates the nuclear receptor LXR. Mol. Cell 28, 91–106 (2007).

    Article  Google Scholar 

  20. Ray, S., Lee, C., Hou, T., Boldogh, I. & Brasier, A. R. Requirement of histone deacetylase1 (HDAC1) in signal transducer and activator of transcription 3 (STAT3) nucleocytoplasmic distribution. Nucleic Acids Res. (2008).

  21. Becker, S., Groner, B. & Muller, C. W. Three-dimensional structure of the Stat3β homodimer bound to DNA. Nature 394, 145–151 (1998).

    Article  CAS  Google Scholar 

  22. Koch, C. A., Anderson, D., Moran, M. F., Ellis, C. & Pawson, T. SH2 and SH3 domains: elements that control interactions of cytoplasmic signaling proteins. Science 252, 668–674 (1991).

    Article  CAS  Google Scholar 

  23. Pawson, T. & Gish, G. D. SH2 and SH3 domains: from structure to function. Cell 71, 359–362 (1992).

    Article  CAS  Google Scholar 

  24. Minami, M. et al. STAT3 activation is a critical step in gp130-mediated terminal differentiation and growth arrest of a myeloid cell line. Proc. Natl Acad. Sci. USA 93, 3963–3966 (1996).

    Article  CAS  Google Scholar 

  25. Maloney, A. et al. Gene and protein expression profiling of human ovarian cancer cells treated with the heat shock protein 90 inhibitor 17-allylamino-17-demethoxygeldanamycin. Cancer Res. 67, 3239–3253 (2007).

    Article  CAS  Google Scholar 

  26. Yoon, J. C. et al. Control of hepatic gluconeogenesis through the transcriptional coactivator PGC-1. Nature 413, 131–138 (2001).

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We thank M. Shanabrough for her technical support and careful revision of this manuscript. Some constructs were obtained from Y. E. Chin, W. Gu, P. Yao, E. Seto and D. Levy. SirT1, PGC-1α adenovirus was a gift from P. P. Puigserver. SirT1 KO MEFs and wild-type MEFs were a gift from L. P. Guarente. Part of this work was supported by an ADA grant to Q. G. (1-08-RA-54) and NIH grants to T. L. H. (DK-08000 and DK-060711), G. I. S. (DK-40936 and DK-076169) and J.L.B. (DK-P30-34989). The preparation of primary hepatocytes was performed in the Liver Center of Yale University School of Medicine. SirT1 ASO and Control ASO were provided by ISIS Pharmaceuticals, Inc.

Author information

Authors and Affiliations

Authors

Contributions

Y.N., T.L.H. and Q.G. designed, executed and analysed most of the experiments and wrote the paper. D.M.E. contributed to the execution of the SirT1-ASO animal experiments and edited the paper. Z.Y. contributed to construction of trunicated STAT3 plasmids. M.D. designed, performed and analysed the animal experiements with EX527 treatement. G.I.S. provided critical models and analysed the data of the animal experiments.

Corresponding authors

Correspondence to Tamas L. Horvath or Qian Gao.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Supplementary information

Supplementary Information

Supplementary Information (PDF 2100 kb)

Rights and permissions

Reprints and permissions

About this article

Cite this article

Nie, Y., Erion, D., Yuan, Z. et al. STAT3 inhibition of gluconeogenesis is downregulated by SirT1. Nat Cell Biol 11, 492–500 (2009). https://doi.org/10.1038/ncb1857

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncb1857

This article is cited by

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing